Plasma alpha 1-antichymotrypsin in liver disease

Area of Science:

• Hepatology
• Clinical Chemistry
• Proteomics

Background:

• Alpha 1-antichymotrypsin (AACT) and alpha 1-antitrypsin (AAT) are serine protease inhibitors.
• Liver disease can affect plasma protein levels.
• Understanding AACT and AAT relationships is crucial for diagnosing and managing liver conditions.

Purpose of the Study:

• To investigate the correlation between plasma AACT and AAT levels in patients with biopsy-proven liver disease.
• To evaluate the utility of the AACT/AAT ratio in identifying PiZ carriers.
• To explore variations in AACT and AAT levels across different liver disease subgroups.

Main Methods:

• Plasma levels of AACT and AAT were measured in 229 patients with biopsy-verified liver disease.
• Statistical analysis, including correlation coefficients, was used to assess the relationship between AACT and AAT.
• The AACT/AAT ratio was analyzed for its effectiveness in identifying PiZ carriers.

Main Results:

• A significant overall correlation was observed between plasma AACT and AAT levels (r = 0.50, p < 0.001).
• Strongest correlations were found in chronic active hepatitis (r = 0.76, p < 0.0001) and alcoholic hepatitis (r = 0.60, p < 0.001).
• Elevated AACT levels were noted in patients with venous congestion; the AACT/AAT ratio showed low sensitivity for PiZ carrier identification.

Conclusions:

• Plasma AACT and AAT levels are significantly correlated in liver disease, with variations across specific conditions.
• The AACT/AAT ratio is not a sensitive or predictive marker for PiZ carriers.
• Hypo-AACT may be linked to liver disease severity or underlying genetic factors.